Cutaneous T-Cell Lymphoma (CTCL) Overview

Save information for later
Sign Up

Learn About Cutaneous T-Cell Lymphoma (CTCL)

What is the definition of Cutaneous T-Cell Lymphoma (CTCL)?
Cutaneous T-cell lymphomas (CTCLs) are a group of disorders characterized by an abnormal accumulation of cancerous T-cells (a type of white blood cells) in the skin resulting in an itchy, red rash that can thicken or form a tumor. CTCLs belong to a larger group of disorders known asnon-Hodgkin's lymphomas. The most common types are mycosis fungoides and Sézary syndrome. In some cases, cancerous T-cells may spread to the lymph nodes and eventually to other body tissues and organs, potentially resulting in serious complications. The specific signs and symptoms vary from person to person. The exact cause of these conditions is unknown.
What are the alternative names for Cutaneous T-Cell Lymphoma (CTCL)?
  • Cutaneous T-cell lymphoma
  • CTCL
Who are the top Cutaneous T-Cell Lymphoma (CTCL) Local Doctors?
Experienced in Cutaneous T-Cell Lymphoma (CTCL)
Dr. George B. Selby
Hematology Oncology | Hematology | Oncology
Experienced in Cutaneous T-Cell Lymphoma (CTCL)
Dr. George B. Selby
Hematology Oncology | Hematology | Oncology

Ou Health Partners Inc

900 Ne 10th St, Ouhp Family Medicine, 
Oklahoma City, OK 
 (18.0 mi)
405-271-4311
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

George Selby is a Hematologist Oncology specialist and a Hematologist in Oklahoma City, Oklahoma. Dr. Selby and is rated as an Experienced provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). His top areas of expertise are Chronic Myelogenous Leukemia (CML), Philadelphia-Negative Chronic Myeloid Leukemia, Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Selby is currently accepting new patients.

Experienced in Cutaneous T-Cell Lymphoma (CTCL)
Dr. Sami M. Ibrahimi
Hematology Oncology | Hematology | Oncology
Experienced in Cutaneous T-Cell Lymphoma (CTCL)
Dr. Sami M. Ibrahimi
Hematology Oncology | Hematology | Oncology

Ou Health Partners Inc

940 Stanton L Young Blvd, 
Oklahoma City, OK 
 (18.0 mi)
405-271-1500
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sami Ibrahimi is a Hematologist Oncology specialist and a Hematologist in Oklahoma City, Oklahoma. Dr. Ibrahimi and is rated as an Experienced provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). His top areas of expertise are Classical Hodgkin Lymphoma, Hodgkin Lymphoma, Large-Cell Immunoblastic Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Ibrahimi is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Experienced in Cutaneous T-Cell Lymphoma (CTCL)
Dr. Jarad I. Levin
Dermatology
Experienced in Cutaneous T-Cell Lymphoma (CTCL)
Dr. Jarad I. Levin
Dermatology

Ou Health Partners Inc

1000 Ne 13th St, Nicholson Clinic, 
Oklahoma City, OK 
 (18.2 mi)
405-271-3445
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jarad Levin is a Dermatologist in Oklahoma City, Oklahoma. Dr. Levin and is rated as an Experienced provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). His top areas of expertise are Hidradenitis Suppurativa, Erythema Nodosum, Autosomal Recessive Hypotrichosis, and Alopecia Areata. Dr. Levin is currently accepting new patients.

View All Doctors
What are the latest Cutaneous T-Cell Lymphoma (CTCL) Clinical Trials?
A Pilot Phase I Trial of IL-21 Expanded, Off the Shelf, Third-Party Natural Killer (NK) Cells in Combination with Mogamulizumab in Patients with Cutaneous T-Cell Lymphomas or Adult T-Cell Leukemia/Lymphomas
A Pilot Phase I Trial of IL-21 Expanded, Off the Shelf, Third-Party Natural Killer (NK) Cells in Combination with Mogamulizumab in Patients with Cutaneous T-Cell Lymphomas or Adult T-Cell Leukemia/Lymphomas
Who is this study for: Patients with Lymphoma
Enrollment Status: Recruiting
Publish Date: February 25, 2025
Intervention Type: Other, Drug, Biological
Study Drugs: Cyclophosphamide, Fludarabine, Mogamulizumab, Natural Killer Cell Therapy
Study Phase: Phase 1

Summary: This phase I trial is to find out the best dose, possible benefits and/or side effects of third-party natural killer cells in combination with mogamulizumab in treating patients with cutaneous T-cell lymphoma or adult T-cell leukemia/lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Immunotherapy with third-party natural killer cells, may induce changes in body'...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Phase I Study With an Expansion Cohort of Tulmimetostat (CPI-0209) in Patients With Mycosis Fungoides and Sézary Syndrome
Phase I Study With an Expansion Cohort of Tulmimetostat (CPI-0209) in Patients With Mycosis Fungoides and Sézary Syndrome
Enrollment Status: Recruiting
Publish Date: February 24, 2025
Intervention Type: Drug
Study Phase: Phase 1

Summary: The hypotheses of this study are that single agent CPI-0209 will be safe and well tolerated in patients with advanced (stage IB-IVB) mycosis fungoides (MF)/Sézary syndrome (SS) who have had at least one prior systemic therapy, and that in these patients, CPI-0209 will demonstrate efficacy and be worth of further study.

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center